Mohammadpour Amir Hooshang, Falsoleiman Homa, Shamsara Jamal, Allah Abadi Ghazaleh, Rasooli Ramin, Ramezani Mohammad
Dept. of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran.
Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran Biomed J. 2014;18(1):23-27. doi: 10.6091/ibj.1211.2013.
Inflammation is involved in development, progression, and complications of atherosclerotic disease. Clinical studies have indicated that the level of monocyte chemoattractant protein 1 (MCP-1), IL-18, and adhesion molecules correlates with the severity of atherosclerosis and can predict future cardiovascular events. Experimental studies have shown pentoxifylline (PTX) reduces these factors in animal models. The purpose of the present pilot study was to evaluate effect of PTX on a group of inflammatory biomarkers in patients with coronary artery disease (CAD).
Forty patients with angiographically documented CAD, who fulfilled inclusion and exclusion criteria, were entered in the double-blind, randomized, pilot clinical study. The patients were randomly given PTX (400 mg three times daily) or placebo (3 tab/day) for 2 months. Serum concentrations of MCP-1, IL-18, intercellular adhesion Molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) were measured before and at the end of intervention by enzyme-linked immunosorbant assay.
Our study showed that the serum levels of ICAM-1 and VCAM-1 was decreased in the study population after two-month treatment (P<0.05).
Based on the results of our pilot study, administration of PTX in CAD patients significantly decreases adhesion molecules levels.
炎症参与动脉粥样硬化疾病的发生、发展及并发症。临床研究表明，单核细胞趋化蛋白1（MCP-1）、白细胞介素-18（IL-18）及黏附分子水平与动脉粥样硬化严重程度相关，并可预测未来心血管事件。实验研究显示，己酮可可碱（PTX）在动物模型中可降低这些因素。本初步研究旨在评估PTX对冠心病（CAD）患者一组炎症生物标志物的影响。
40例经血管造影证实患有CAD且符合纳入及排除标准的患者进入双盲、随机、初步临床研究。患者随机给予PTX（每日3次，每次400 mg）或安慰剂（每日3片），疗程2个月。干预前及干预结束时采用酶联免疫吸附测定法测量血清MCP-1、IL-18、细胞间黏附分子1（ICAM-1）及血管细胞黏附分子1（VCAM-1）浓度。
我们的研究表明，治疗2个月后，研究人群血清ICAM-1和VCAM-1水平降低（P<0.05）。
基于我们初步研究的结果，CAD患者服用PTX可显著降低黏附分子水平。
